Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Joao V. Alessi(Hospital Sírio-Libanês), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Federica Pecci(University of Parma), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Rosa L. Frias(Dana-Farber Cancer Institute), Jacklynn V. Egger(Memorial Sloan Kettering Cancer Center), Deepti Venkatraman(Dana-Farber Cancer Institute), Grace M. Hambelton(Massachusetts General Hospital), Hyesun Park(Brigham and Women's Hospital), Biagio Ricciuti(Harvard University), Xihong Lin(Harvard University), Victor R. Vaz(Dana-Farber Cancer Institute), Arielle Elkrief(Centre Hospitalier de l’Université de Montréal), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Claudia Angela Maria Fulgenzi(Università Campus Bio-Medico), Subba R. Digumarthy(Massachusetts General Hospital), Bruce E. Johnson(Harvard University), Adriana P C Barrichello(Dana-Farber Cancer Institute), Alessio Cortellini(Campus Bio Medico University Hospital), Gonzalo Recondo(Dana-Farber Cancer Institute), Mizuki Nishino(Brigham and Women's Hospital), Alessandro Di Federico(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giuseppe Lamberti(Dana-Farber Cancer Institute), Justin F. Gainor(Harvard University), W. Marston Linehan(Harvard University), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), David C. Christiani(Harvard University), Xinan Wang(Harvard University)
Journal of Thoracic Oncology
February 10, 2023
Cited by 91


Related Papers